GSK joins IMPRESS-Norway
IMPRESS-Norway has been open for inclusion for over two years and so far more than 1000 patients have had their tumor sequenced through InPreD and over 200 patients have been offered a new treatment. The study is dynamic in the way that new companies and new drugs can be added to the study all the …